Movement disorders clinical practice · 2026
Earlier Postural and Cognitive Milestones in Parkinson's Disease with Comorbid Myasthenia Gravis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pecoraro Pasquale Maria, Mangiardi Marilena, Abanto Jesus, Duque Kevin R, de la Esperanza Blanca Talavera, Yu Zheming, Deraz Heba A, Bell Ansley, Espay Alberto J, Marsili Luca
Аннотация
BACKGROUND: The coexistence of Parkinson's disease (PD) and myasthenia gravis (MG) is poorly characterized. Overlapping axial symptoms and fatigability may complicate diagnosis and interpretation of PD-related milestones.
OBJECTIVES: The aim of the study was to characterize the phenotype of coexistent PD and MG (PD + MG) and explore differences in the timing of PD-related milestones compared to matched PD-only controls.
METHODS: In this matched-cohort study, PD patients with serologically and/or electrophysiologically confirmed MG were retrospectively identified from clinical records and compared with sex-, race-, age-at-PD-onset-, disease-duration-matched PD (PD-only) controls prospectively assessed within the Cincinnati Cohort Biomarker Program. Disease milestones were Hoehn & Yahr (H&Y) ≥ 3 and Montreal Cognitive Assessment (MoCA) < 26. Time-to-event analyses used Kaplan-Meier and Cox proportional-hazards models adjusted for sex, race, age-at-PD onset, and disease duration.
RESULTS: We identified 21 PD + MG patients with predominantly ocular MG and autoimmune diseases. Compared to 210 matched PD-only controls, postural instability (71% vs. 12%) and cognitive impairment (57% vs. 4.8%) were more prevalent (P < 0.001). Median time from PD onset to H&Y ≥ 3 and MoCA < 26 was shorter in PD + MG, with milestones documented at or near PD diagnosis, versus 5 and 7 years in controls (P < 0.001). PD + MG patients showed increased adjusted hazard ratios (HR) for H&Y ≥ 3 (HR: 10.6; 95% confidence interval [CI], 3.83-29.4; P < 0.001) and MoCA < 26 (HR: 35.3; 95% CI, 12.8-97.1; P < 0.001).
CONCLUSIONS: PD + MG was associated with earlier documented postural and cognitive milestones than matched PD-only controls, although interpretation warrants caution given the retrospective ascertainment for PD + MG cases. Oculobulbar symptoms, disproportionate axial impairment, or fluctuating weakness should prompt investigation as potential indicators of concomitant MG.
OBJECTIVES: The aim of the study was to characterize the phenotype of coexistent PD and MG (PD + MG) and explore differences in the timing of PD-related milestones compared to matched PD-only controls.
METHODS: In this matched-cohort study, PD patients with serologically and/or electrophysiologically confirmed MG were retrospectively identified from clinical records and compared with sex-, race-, age-at-PD-onset-, disease-duration-matched PD (PD-only) controls prospectively assessed within the Cincinnati Cohort Biomarker Program. Disease milestones were Hoehn & Yahr (H&Y) ≥ 3 and Montreal Cognitive Assessment (MoCA) < 26. Time-to-event analyses used Kaplan-Meier and Cox proportional-hazards models adjusted for sex, race, age-at-PD onset, and disease duration.
RESULTS: We identified 21 PD + MG patients with predominantly ocular MG and autoimmune diseases. Compared to 210 matched PD-only controls, postural instability (71% vs. 12%) and cognitive impairment (57% vs. 4.8%) were more prevalent (P < 0.001). Median time from PD onset to H&Y ≥ 3 and MoCA < 26 was shorter in PD + MG, with milestones documented at or near PD diagnosis, versus 5 and 7 years in controls (P < 0.001). PD + MG patients showed increased adjusted hazard ratios (HR) for H&Y ≥ 3 (HR: 10.6; 95% confidence interval [CI], 3.83-29.4; P < 0.001) and MoCA < 26 (HR: 35.3; 95% CI, 12.8-97.1; P < 0.001).
CONCLUSIONS: PD + MG was associated with earlier documented postural and cognitive milestones than matched PD-only controls, although interpretation warrants caution given the retrospective ascertainment for PD + MG cases. Oculobulbar symptoms, disproportionate axial impairment, or fluctuating weakness should prompt investigation as potential indicators of concomitant MG.